Cadrenal Therapeutics, Inc. Annual Operating Income (Loss) in USD from 2022 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Cadrenal Therapeutics, Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2022 to 2023.
  • Cadrenal Therapeutics, Inc. Operating Income (Loss) for the quarter ending September 30, 2024 was -$2.46M, a 115% decline year-over-year.
  • Cadrenal Therapeutics, Inc. Operating Income (Loss) for the twelve months ending September 30, 2024 was -$7.95M, a 6.73% decline year-over-year.
  • Cadrenal Therapeutics, Inc. annual Operating Income (Loss) for 2023 was -$7.63M, a 183% decline from 2022.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$7.63M -$4.93M -183% Jan 1, 2023 Dec 31, 2023 10-K 2024-03-11
2022 -$2.7M Jan 25, 2022 Dec 31, 2022 10-K 2024-03-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.